Prime Medicine Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, Prime Medicine stock has a consensus rating of "Buy" and an average price target of $7.11. The average 1-year stock price forecast is 99.16% higher than the current stock price, while the lowest is $4.25 (+19.05%) and the highest is $11 (+208.12%).

Price Target: $7.11 (+99.16%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$4.25	$7.11	$7.00	$11
Change	+19.05%	+99.16%	+96.08%	+208.12%

Analyst Ratings

The average analyst rating for Prime Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	8	8	8	9	9	10
Buy	1	1	1	1	1	1
Hold	4	4	4	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	13	13	13	13	13	14

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Keay Nakae Chardan Capital	Chardan Capital	Buy Maintains $7	Buy	Maintains	$7	+96.08%	Aug 25, 2026
Unknown Analyst BMO Capital No rating	BMO Capital	Buy Initiates $9	Buy	Initiates	$9	+152.10%	Aug 18, 2026
Cory Jubinville, PhD LifeSci Capital	LifeSci Capital	Buy Reiterates $6	Buy	Reiterates	$6	+68.07%	Aug 17, 2026
Terence Flynn Morgan Stanley	Morgan Stanley	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Aug 10, 2026
Arthur He CFA H.C. Wainwright	H.C. Wainwright	Buy Maintains $8	Buy	Maintains	$8	+124.09%	Aug 10, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

11.83M

from 4.63M

155.30%

from 4.63M

Revenue Next Year

13.38M

from 11.83M

13.16%

from 11.83M

EPS This Year

-0.94

from -1.35

EPS Next Year

-0.89

from -0.94

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	2.98M	4.63M	11.83M
Revenue Growth	-	-	-	-	55.28%	155.30%
Operating Income	-84.47M	-116.54M	-191.29M	-202.47M	-208.35M	-181.84M
Net Income	-165.37M	-121.82M	-198.13M	-195.88M	-201.14M	-181.92M
EPS	-	-	-	-	-1.35	-0.94
Free Cash Flow	-6.80M	-117.62M	-96.21M	-114.57M	-85.37M	-158.36M
No. Analysts	-	-	-	-	-	14

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	53.0M
Avg	11.8M
Low	2.0M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	1,044.4%
Avg	155.3%
Low	-56.8%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.81
Avg	-0.94
Low	-1.11

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-